ArticleRevista da Associacao Medica Brasileira (1992)2026
Evaluation of ferroptosis markers and laboratory findings in patients with juvenile idiopathic arthritis.
Article in Revista da Associacao Medica Brasileira (1992), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveJuvenile idiopathic arthritis is the most prevalent chronic rheumatic disease of childhood. Ferroptosis is a distinct, regulated form of cell death that is iron-dependent and driven by the accumulation of lipid peroxides on cell membranes. The aim of this study was to measure the soluble transferrin receptor and malondialdehyde levels as ferroptosis markers in Turkish children with Juvenile idiopathic arthritis. We also evaluated the laboratory findings in the patients.
methodsThirty children diagnosed with Juvenile idiopathic arthritis and 30 healthy children were included in the study. The sTfR1 and the malondialdehyde levels were measured by enzyme-linked immunosorbent assay.
resultsThe mean age of the patient group was 10.13±3.98, and the mean age of the control group was 10.67±3.21. Blood soluble transferrin receptor and malondialdehyde levels did not differ between the patient and control groups (p>0.05). In contrast, the p-value for the malondialdehyde results was statistically borderline. In the patient group, sedimentation rates were found to correlate with serum amyloid A, C-reactive protein levels. In addition, the highest malondialdehyde levels were found in systemic Juvenile idiopathic arthritis, and the highest soluble transferrin receptor levels were found in psoriatic arthritis subtypes. Both malondialdehyde and soluble transferrin receptor levels were lowest in those treated with methotrexate.
conclusionAlthough our findings show that soluble transferrin receptor and malondialdehyde levels did not differ between patient and control groups, larger-scale studies are needed to evaluate more specific biomarkers and/or targeted tissue sampling in different subtypes, controlling for confounding factors such as treatment. This could open new horizons for therapies targeting ferroptosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.